| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | nPKC eta; PKC h; PKC L; PKCh; PKCL; Prkch; PRKCL; Protein kinase C eta |
| Entrez GeneID | 5583 |
| WB Predicted band size | Calculated MW: 78 kDa; Observed MW: 40,78 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PKC eta |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PKC η抗体的模拟参考文献示例(供参考，实际文献需通过学术数据库检索获取)：
1. **文献名称**：*"Protein kinase C eta regulates keratinocyte differentiation through phosphorylation of STAT3"*
**作者**：Smith A, et al.
**摘要**：研究利用PKC η特异性抗体，通过Western blot和免疫组化分析发现PKC η通过磷酸化STAT3信号通路调控表皮角质形成细胞分化，提示其在皮肤屏障功能中的关键作用。
2. **文献名称**：*"PKCη-mediated resistance to chemotherapy in ovarian cancer cells"*
**作者**：Chen L, et al.
**摘要**：该文献通过shRNA敲低PKC η并结合抗体检测蛋白表达，发现PKC η通过激活Akt通路增强卵巢癌细胞对顺铂的耐药性，为靶向PKC η的癌症治疗提供依据。
3. **文献名称**：*"Interaction between PKCη and Raf-1 in MAPK signaling pathway"*
**作者**：Tanaka K, et al.
**摘要**：利用免疫共沉淀(Co-IP)和PKC η抗体，证实PKC η与Raf-1在MAPK通路中形成复合物，调控细胞增殖和凋亡，揭示其在肿瘤发生中的潜在机制。
4. **文献名称**：*"Development of a monoclonal antibody targeting PKCη for therapeutic inhibition in inflammatory diseases"*
**作者**：Gupta R, et al.
**摘要**：研究报道了一种新型PKC η单克隆抗体的开发，通过体外实验和小鼠模型证明其可特异性抑制PKC η活性，减轻炎症反应，提示其治疗自身免疫疾病的潜力。
---
**注意**：以上为模拟内容，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索关键词(如"PKC eta antibody" "PRKCH signaling")获取最新研究。建议结合具体研究场景(如疾病模型、实验技术)筛选文献。
The protein kinase C (PKC) family comprises a group of serine/threonine kinases that play critical roles in cellular signaling, regulating processes such as proliferation, differentiation, and apoptosis. PKC eta (η), also known as PRKCH, is a member of the novel PKC subfamily (nPKC), characterized by its calcium-independent activation and dependence on diacylglycerol (DAG) for signaling. Unlike classical PKC isoforms, PKC eta lacks a calcium-binding domain but retains the C1 domain for DAG interaction and the C2 domain for membrane targeting. It is widely expressed in epithelial tissues, the skin, and the central nervous system, where it modulates cell polarity, differentiation, and stress responses.
Antibodies targeting PKC eta are essential tools for studying its expression, localization, and function in both normal physiology and disease. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research has linked PKC eta to various pathological conditions, including cancer, where it may act as a tumor suppressor or promoter depending on context. For example, PKC eta is implicated in skin carcinogenesis and chemoresistance in certain cancers. Dysregulation of its signaling has also been associated with diabetic complications and neurodegenerative disorders. Validating PKC eta antibodies for specificity and cross-reactivity is crucial, given the structural similarities among PKC isoforms. Such antibodies facilitate mechanistic studies, biomarker discovery, and therapeutic targeting, underscoring their importance in translational research.
×
